angiotensin ii has been researched along with Muscular Weakness in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chakravarthi, S; Fuloria, NK; Fuloria, S; Kumar, DH; Kumari, U; Meenakshi, DU; Narra, K; Patel, TD; Sekar, M; Sharma, PK; Subramaniyan, V; Vanteddu, VG | 1 |
| Arkell, AM; Brunt, KR; Eadie, AL; Foster, AJ; Gillis, TE; Huber, JS; Murrant, CL; Platt, MJ; Romanova, N; Simpson, JA; Wright, DC | 1 |
| Hall, SE; Kwon, OS; Morton, AB; Powers, SK; Smuder, AJ; Sollanek, KJ; Talbert, EE; Toklu, HZ; Tumer, N; Wiggs, MP | 1 |
1 review(s) available for angiotensin ii and Muscular Weakness
| Article | Year |
|---|---|
Etiopathophysiological role of the renin-angiotensin-aldosterone system in age-related muscular weakening: RAAS-independent beneficial role of ACE2 in muscle weakness.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme 2; Humans; Muscle Weakness; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 2022 |
2 other study(ies) available for angiotensin ii and Muscular Weakness
| Article | Year |
|---|---|
Central-acting therapeutics alleviate respiratory weakness caused by heart failure-induced ventilatory overdrive.
Topics: Angiotensin II; Animals; Blood-Brain Barrier; Diaphragm; Eukaryotic Initiation Factor-2; Heart Failure; Lung; Male; Mice; Muscle Weakness; Phosphorylation; Respiration; Signal Transduction | 2017 |
AT1 receptor blocker losartan protects against mechanical ventilation-induced diaphragmatic dysfunction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Diaphragm; Enalapril; Female; Losartan; Muscle Weakness; Rats; Rats, Sprague-Dawley; Respiration, Artificial | 2015 |